Symptomatic osteochondral lesions of the patellofemoral joint are clinically challenging to manage because of the limited healing potential of articular cartilage; the complex morphology of the patellofemoral joint; the heterogeneity of the articular surface between patients; and high stresses across the joint, which can be altered by malalignment, tilt, or maltracking. Indications for surgery include traumatic lesions, osteochondritis dissecans, and high-grade chondromalacia in association with persistent pain despite a course of nonsurgical management. Various techniques have been described for managing symptomatic osteochondral lesions of the patellofemoral joint, including microfracture, osteochondral autograft transplantation, and biologic cell transplantation, including autologous chondrocyte implantation. Salvage techniques (eg, fresh allograft) may provide satisfactory outcomes after a failed attempt at surgical management. Irrespective of the surgical technique used, outcomes are generally worse in the patellofemoral compartment than in the tibiofemoral joint. The concomitant management of associated pathology, including patellar malalignment, is recommended because it has been shown to improve the success of cartilage restoration procedures.
From Washington University Orthopedics, Chesterfield, MO (Dr. Brophy) and Washington University Orthopedics, Washington University in St. Louis, St. Louis, MO (Dr. Wojahn and Dr. Lamplot).
Dr. Brophy or an immediate family member is a member of a speakers’ bureau or has made paid presentations on behalf of Arthrex; has stock or stock options held in Ostesys; has received research or institutional support from Orteq Sports Medicine; and serves as a board member, owner, officer, or committee member of the American Academy of Orthopaedic Surgeons, the American Orthopaedic Association, the American Orthopaedic Society for Sports Medicine, and the Orthopaedic Research Society. Neither of the following authors nor any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article: Dr. Wojahn and Dr. Lamplot.
Received August 23, 2015
Received in revised form May 15, 2016
Received in revised form March 10, 2016
Accepted June 07, 2016